Please assess the completion status of the following clinical trial:

Trial Title: SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or female medical non-ICU patients aged 18 - 70 years.~2. A known history of type 2 diabetes \> 3 months, receiving either diet alone, oral antidiabetic agents (excluding DPP4 inhibitors), or low-dose (≤ 0.5 units/kg/day) insulin therapy.~3. Subjects with BG \>180 mg and \< 400 mg/dL at the time of randomization without laboratory evidence of diabetic ketoacidosis (serum bicarbonate \< 18 mEq/L or positive serum or urinary ketones).~4. Written informed consent.~Exclusion Criteria:~1. Age \< 18 or \> 70 years.~2. Subjects with increased BG concentration but without a history of diabetes (stress hyperglycemia).~3. Subjects with a history of type 1 diabetes.~4. Patients with a history of diabetic ketoacidosis or hyperosmolar state.~5. Acute critical illness or coronary artery bypass graft (CABG) surgery is expected to require admission to a critical care unit.~6. Subjects with gastrointestinal obstruction, adynamic ileus, or those expected to require gastrointestinal suction.~7. Unable to take oral food or medications.~8. Patients with clinically relevant pancreatic or gallbladder disease.~9. Patients with significant hepatic disease (Child-Pugh score B or C) or impaired renal function (GFR \< 50 ml/min).~10. Treatment with oral or injectable corticosteroid.~11. Mental condition renders the subject unable to understand the study's nature, scope, and possible consequences.~12. Female subjects are pregnant or breastfeeding at the time of enrollment into the study.~13. Hypersensitivity to sitagliptin or another contraindication to DPP4 inhibitors.~14. Subject unable to give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin + glargine (Type: EXPERIMENTAL): Sitagliptin and glargine once daily + correction doses of lispro if needed.
- Basal-plus (Type: ACTIVE_COMPARATOR): Glargine once daily plus correction doses of lispro if needed.

Based on this trial design, predict the completion outcome and termination type (if applicable).